Treatment
Rituximab
4
Conditions
248
Trials
37K
Participants
40%
Average Safety
Condition Evidence
Chronic kidney disease due to glomerulonephritis
80 trials · 8,000 participants
78% effectiveness · 35% safety
Encephalitis
6 trials · 1,000 participants
75% effectiveness · 40% safety
Lupus
36 trials · 8,000 participants
70% effectiveness · 45% safety
Rheumatoid arthritis
126 trials · 20K participants
76% effectiveness · 38% safety